STAT+: Shingles vaccine may lower dementia risk, new study finds
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Shingrix vaccination was associated with a 24% lower likelihood of developing dementia over four years among elderly nursing home residents, compared with unvaccinated peers
- The study was published this week in the peer-reviewed journal Annals of Internal Medicine and examined outcomes over a four-year follow-up period
- Shingrix is the only shingles vaccine currently available in the United States, making it the sole candidate for the observed protective effect
- The research adds to a growing body of evidence linking viral infections to cognitive decline, suggesting the dementia connection extends beyond chickenpox and shingles exposure alone
Why it matters: The 24% reduction in dementia likelihood over four years — observed in a vulnerable nursing home population — gives clinicians and older adults a potential second reason to get Shingrix beyond shingles prevention. The finding adds concrete peer-reviewed data to the emerging hypothesis that viral infections contribute to cognitive decline.
